What does low ferritin with normal haemoglobin mean?

How it works

Camaschella 2015 (NEJM 372(19):1832-1843, PMID 25946282) and Camaschella 2019 (Blood 133(1):30-39, PMID 30401704) describe the staged model. Tissue iron-dependent processes (mitochondrial electron transport, thyroid peroxidase, dopamine synthesis via tyrosine hydroxylase) can be impaired before haemoglobin drops, which is the mechanistic basis for IDWA potentially producing symptoms before frank anaemia. Murray-Kolb 2007 (Am J Clin Nutr 85(3):778-787, PMID 17344500) showed reduced cognitive performance in young women with IDWA, with improvement on iron repletion.

Effective dose

Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639) demonstrated 60 mg elemental iron on consecutive days produced hepcidin elevations reducing absorption from the next dose by 35-45%. Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957) and Stoffel 2020 (Haematologica 105(5):1232-1239) extended findings to alternate-day dosing in iron-deficient and iron-depleted women.

Timing

If ferritin remains low despite adequate adherence, reconsider underlying cause workup. No specific ferritin target per BSG 2021; supplementation endpoint is clinical (resolution of symptoms or restoration of stores) rather than numerical. For IDA (low ferritin AND low Hb), continue oral iron 3 months after Hb normalisation per BSG 2021.

Safety profile

Self-supplementation with iron without confirmed deficiency can be harmful, particularly in undiagnosed haemochromatosis (HFE C282Y homozygotes roughly 1 in 200 in UK Northern European populations) or other iron-loading conditions. Paediatric accidental ingestion is the standard reason iron supplements should be kept secured. Iatrogenic iron overload with long-term unsupervised supplementation is a documented risk. Inflammation must be excluded before interpreting ferritin: ferritin is an acute-phase reactant and rises in inflammation, infection, malignancy, liver disease, and obesity, independent of iron status (Camaschella 2019; Ganz 2019 NEJM 381(12):1148-1157, PMID 31532961).

Special populations

Pregnancy: NICE NG201 antenatal care pathway covers screening and management. Athletes: AIS guidelines and recent reviews suggest more permissive supplementation thresholds in this group, though specific RCT evidence base is limited. RLS: AASM 2024 sets RLS-specific ferritin thresholds well above general iron deficiency cut-offs (75 µg/L or below for oral iron, 75-100 µg/L for IV iron). Frequent blood donors: post-donation iron replacement increasingly considered (Smith 2014 Cochrane CD009532; Pasricha 2017 Transfusion 57:1922-1929). Older adults: iron deficiency requires GI workup per BSG 2021 to exclude malignancy. Children: separate paediatric guidance applies.

Interactions

The clinical evidence on iron repletion for fatigue in non-anaemic adults is mixed: positive in Verdon 2003 (BMJ 326(7399):1124, PMID 12763985) and Vaucher 2012 (CMAJ 184(11):1247-1254, PMID 22777991); negative in Keller 2020 (Sci Rep 10:14219, PMID 32848185); Krayenbuehl 2011 (Blood 118(12):3222-3227, PMID 21705493) showed benefit only in subgroup with ferritin 15 ng/mL or below. Dugan 2022 abridged Cochrane (J Cachexia Sarcopenia Muscle 13(6):2637-2649, PMID 36321348) reports SMD -0.30 (95% CI -0.52 to -0.09) with low to very low evidence quality across 21 RCTs and 3514 participants.

Guideline positions

Ganz 2019 (NEJM 381(12):1148-1157, PMID 31532961) covers anaemia of inflammation. Verdon 2003, Vaucher 2012, Krayenbuehl 2011, Keller 2020, and Dugan 2022 form the IDWA-fatigue evidence chain. Murray-Kolb 2007 (Am J Clin Nutr 85(3):778-787, PMID 17344500) anchors the cognition signal. AASM 2024 (Winkelman et al, J Clin Sleep Med 21(1):137-152, PMID 39324694) sets the RLS-specific ferritin thresholds. The Stoffel/Moretti programme underpins the alternate-day dosing approach.

Practical framework

GI investigation is indicated for unexplained iron deficiency in postmenopausal women and all men, even without anaemia, where occult GI bleeding (including malignancy) must be excluded. In premenopausal women, NICE NG88 heavy menstrual bleeding pathway is the leading underlying-cause workup. Supplementation in IDWA is more clearly indicated in: symptomatic patients (fatigue not explained otherwise, hair shedding, exercise intolerance, restless legs); RLS where guidelines specify higher ferritin targets; pregnancy planning; endurance athletes during heavy training; repeat blood donors with documented iron depletion. Failure to identify or address the underlying cause is the most common reason iron repletion fails. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: a normal ferritin during inflammation reflects adequate iron stores. Ferritin is an acute-phase reactant; CRP-paired interpretation is essential. In confirmed inflammation, alternative thresholds apply (some references use ferritin below 70 µg/L; TSAT below 16-20% is more reliable because TSAT is not an acute-phase reactant).

Claim: switching between ferrous sulphate, fumarate, and gluconate for tolerability is evidence-supported. BSG 2021 explicitly states it is not. The Tolkien 2015 meta-regression found no significant relationship between iron form and GI side-effect rate.